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Abstract 
Neurogenic inflammation is evoked by neuropeptides released from primary afferent terminals and, 
presumably, by other secondarily released inflammatory mediators. This study examines whether 
prostaglandins might participate in the development of neurogenic inflammation in humans and whether 
cyclooxygenase inhibitors have any anti-inflammatory effect on this type of inflammation. In healthy 
volunteers, neurogenic inflammation was elicited by epicutaneously applied capsaicin (1 %), after systemic 
pretreatment with acetylsalicylic acid, or topically applied indomethacin compared to pretreatment with 
saline or vehicle, respectively. The extent of neurogenic inflammation was quantified by planimetry of 
visible flare size and recording the increase of superficial cutaneous blood flow (SCBF) with a laser Doppler 
flowmeter. Capsaicin-induced flare sizes and outside SCBF (both representing neurogenically evoked 
inflammation) were unaffected by acetylsalicylic acid or indomethacin. Only the capsaicin-induced increase 
; of inside SCBF was attenuated by local pretreatment with indomethacin, reflecting the participation of 
. prostaglandins in the inflammatory response of those areas which were in direct contact with capsaicin. 
Introduction 
Neurogenic inflammation may be involved in a 
variety of diseases including e.g. arthritis, skin 
inflammation, and asthma (cf. [1, 2]). The medi-
ators of this inflammation include neuropeptides 
such as substance P and CGRP released from 
, afferent nerve terminals, and putative secondarily 
released or synthetized inflammatory mediators. 
Histamine seems to play no primary role in the 
development of capsaicin-induced inflammation in 
human skin [3]. 
. • Author for correspondence. 
This double-blind, randomized, placebo-controlled 
study examines whether prostaglandins might be 
involved in the development of neurogenic inflam-
mation, and whether cyclooxygenase inhibitors 
such as acetylsalicylic acid (ASA) and indometha-
cin have any anti-inflammatory effect <on acutely 
induced neurogenic inflammation in humans. 
Materials and methods 
Subjects 
Twelve healthy volunteers, 6 women and 6 men, 
aged 22~28 years, with no history of pain, skin 
C26 
disease, or dysfunction of the upper extremItIes 
took part in this study and gave informed consent 
to the double-blind, placebo-controlled design. The 
study was approved by the Ethics Committee of 
Wiirzburg University. 
All experiments were performed in a quiet room 
maintained at 22-25 QC after subjects had acclima-
tised to room temperature for at least 30min. To 
ensure drug washout and skin recovery, experi-
ments were separated by 1-2 weeks. 
Induction of" neurogenic inflammation 
Neurogenic inflammation was induced with capsai-
cin (l %) using a modified patch technique. The 13 
x 18 mm2 area of commercially available plasters 
were soaked with 0.1 ml capsaicin (l %) and applied 
on volar forearm skin for 25 min. 
Quantification of neurogenic inflammation 
After the plaster had been removed and a 5 min 
period for drying had elapsed, the inflammatory 
response was quantified by planimetry of visible 
flare size and by recording the superficial cutaneous 
blood flow (SCBF) underlying (inside SCBF) and 
surrounding (outside SCBF) the application site of 
capsaicin with laser Doppler flowmetry (Periflux 
PF3, Perimed, Stockholm, Sweden). Representative 
inside SCBF was calculated as the mean of values 
at four measuring points inside the plaster applica-
tion side and representative outside SCBF as the 
mean of eight measuring points each 8 mm outside 
the plaster application side. The results expressed 
as mean ±SD were tested for significance (p < 0.05) 
using the two-tailed Wilcoxon-test. 
Drug application 
A. Acetylsalicylic acid (ASA). Prior to any drug 
application the assigned skin areas were pretreated 
with 10% DMSO for 1 h under occlusive tapes to 
improve and standardize cutaneous capsaicin 
absorption. 
A control inflammatory response was induced on 
one forearm, and on the contralateral side the same 
procedure was repeated after ASA (lOmg/kg body 
weight, Aspisol, Bayer, Leverkusen) or the same 
volume of saline (0.9%) had been injected intra-
venously. 
B. Indomethacin. Prior to capsaicin testing, the 
assigned skin area was pretreated with topically 
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applied indomethacin or vehicle (Elmetacin, Luit-
pold-Werk, Miinchen, Germany) for 4h. The plas-
ters (60 x 40mm 2 ) soaked with either 4ml indom-
ethacin (32 mg) or 4 ml vehicle were applied in 
randomized order under occlusive tapes to either 
forearm skin. 
Results 
Following systemic saline injection, flare sizes 
(l753.0±471.9mm 2) and capsaicin-induced in-
crease of inside SCBF (96.3 ± 25.3 perfusion units 
(p.u.)) and outside SCBF (65.8 ± 27.7 p.u.) were not 
different from those seen on the control fore-
arm (l755.0±471.9mm 2, 108.4± 19.3p.u., 71.5 
± 36.1 p.u.). Intravenously injected ASA had no 
effect on inside SCBF (98.6 ± 15.9 p.u.), outside 
SCBF (65.0±27.7p.u.), and flare sizes (1607.7 
± 872.4 mm 2 ) compared to controls and placebo 
(saline). 
Capsaicin-induced outside SCBF (78.1 ± 31.3 p.u.) 
and flare size (1959.3 ± 687.1 mm2 ) were unaffected 
after local pretreatment with indomethacin (81.3 
±25.0p.u., 2166.8±559.1 mm 2 , respectively) but 
increase of inside SCBF (105.3 ± 27.5 p.u.) was sig-
nificantly (p < 0.05) lower compared to pretreat-
ment with vehicle (120.9 ± 23.1 p.u.). 
Discussion 
The results indicate that potent cyclooxygenase 
inhibitors, such as intravenously administered ace-
tylsalicylic acid in an anti-inflammatory dose, or 
indomethacin in high local concentrations have no 
influence on capsaicin-induced neurogenic inflam-
mation. We propose, therefore, that prostaglandins 
are not major inflammatory mediators in neuro-
genic inflammation in human skin; consequently, 
cyclooxygenase inhibitors cannot be expected to 
reduce neurogenically evoked inflammation. 
The reduction in the extent of the inner SCBF 
increase following local indomethacin pretreat-
ment confirms the assumption that the inflamma-
tory response underlying the contact area of capsai-
cin to skin is of more complex origin, presumably 
including the participation of prostaglandins. It 
also supports the contention that this inflamed area 
should be distinguished from the neurogenic in-
flammation proper represented by outside SCBF 
and flare. 
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